
Revolutionizing Breast Cancer Treatment: The Emerging Arsenal Against HER2-Positive Disease
The treatment of HER2-positive breast cancer is rapidly evolving with innovative, personalized therapies matched to unique tumor characteristics. A diverse selection of treatments includes monoclonal antibodies, HER2-targeted tyrosine kinase inhibitors, and antibody-drug conjugates, empowering oncologists with strategic flexibility. Personalized medicine focuses on